| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5dee4af4418bb4b6b6e4f37dfa170ea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y111-01009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-15001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4813 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate |
2008-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5d33776ef9755a7c5776515ce08f4ef |
| publicationDate |
2009-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009137617-A1 |
| titleOfInvention |
Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease |
| abstract |
This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a diabetic subject, treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype; and methods of treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10058542-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11013730-B1 |
| priorityDate |
2007-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |